Insight Molecular Diagnostics price to book ratio IMDX

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 163×; Nov 2025
10-year median: 4.0×
10-year range: 0.4× to 173×
Peer median: 1.9×

Insight Molecular Diagnostics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Nov 2025, at 163×.

On the days it had one over the last ten years, its median was 4.0×, from 0.4× in Mar 2023 to 173× in Oct 2025.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	163×	3.5×	173×
2024	3.7×	0.6×	4.7×
2023	0.5×	0.4×	1.3×
2022	0.5×	0.5×	2.5×
2021	2.0×	2.0×	14.1×
2020	4.6×	2.1×	6.2×
2019	3.8×	2.3×	66.7×
2018	7.9×	5.3×	17.5×
2017	18.2×	11.0×	42.0×
2016	16.0×	11.1×	34.2×

Against its peers

Companies in Healthcare nearest Insight Molecular Diagnostics' size, closest first, today.

Company	Price to book ratio
IMDXInsight Molecular Diagnostics	n/m
ICCCImmucell	3.0×
KEQUKewaunee Scientific	1.3×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
APTAlpha Pro Tech	0.9×
ATNMActinium Pharmaceuticals	1.6×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
ELMDElectromed	4.1×
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Insight Molecular Diagnostics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.